EAM
SGMO

EverPoint Asset Management’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

EverPoint Asset Management’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-50,000
Closed -$761K – 583
2014
Q4 		$761K Hold
50,000
– – 0.02% 416
2014
Q3 		$539K Buy
+50,000
New +$653K 0.01% 393

Other funds holding SGMO

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

EverPoint Asset Management's SGMO Position: Q2 2016 in Review

EverPoint Asset Management sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q2 2016, closing a stake of 1,500,000 shares — an estimated $9.07M sold.

EverPoint Asset Management first reported a position in SGMO in Q2 2014 and held it in 7 quarters. The position peaked at $17.3M in Q4 2015. 136 funds tracked by Wall St. Rank hold SGMO as of Q2 2016.

  • EverPoint Asset Management reported no remaining SANGAMO THERAPEUTICS INC position as of Q2 2016 after selling out during the quarter.
  • EverPoint Asset Management sold 1,500,000 SANGAMO THERAPEUTICS INC shares in Q2 2016, an estimated $9.07M.
  • EverPoint Asset Management first reported a position in SANGAMO THERAPEUTICS INC in Q2 2014 and held it in 7 quarters.
  • EverPoint Asset Management's SANGAMO THERAPEUTICS INC position peaked at $17.3M in Q4 2015.
  • 136 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q2 2016.

Based on EverPoint Asset Management's 13F filing for Q2 2016, filed 15 Aug 2016.